Corbus Pharmaceuticals

Corbus Pharmaceuticals

Corbus Pharmaceuticals was founded in 2014 by CEO Yuval Cohen in Norwood, Massachusetts. The company operates as a clinical-stage precision oncology and immunology firm; it is not a family office, fund, or allocator but rather an R&D-driven biotech listed on the NASDAQ. Corbus originally built its platform around synthetic oral endocannabinoid-mimetic drugs, advancing its lead candidate lenabasum through Phase 3 trials for systemic sclerosis and cystic fibrosis before those programs failed to meet endpoints in 2020 and 2021. Following the lenabasum setbacks, Corbus retooled its strategy around integrin-targeted antibody-drug conjugates and small-molecule immunomodulators. Its pipeline now centers on CRB-701, an anti-avβ6 ADC in-licensed from CSPC Pharmaceutical Group for solid tumors, and CRB-913, an inverse agonist at the CB1 receptor licensed from Jenrin Discovery for obesity and metabolic disease. The company executes its programs through a lean internal team and a network of contract research organizations. Its geographic footprint remains concentrated in the United States, with clinical trial sites and licensing partnerships extending into China through the CSPC deal and into broader global territories through standard trial networks. Corbus is a fully virtualized biotech with no disclosed professional headcount for its direct employee base, though it reports an SEC-filed public-company infrastructure with typical C-suite and board functions. As of September 2024, the company announced that the FDA had cleared the Investigational New Drug application for its next-generation CB1 inverse agonist, triggering a milestone payment to partner Jenrin Discovery and enabling a planned Phase 1 trial in obesity. The company has historically funded operations through public equity offerings and licensing deals rather than institutional LP allocations, philanthropic vehicles, or co-investment clubs. Corbus's structural differentiator is its concentrated public-market operating model combined with an in-licensing hub strategy: rather than building discovery engines internally, the firm identifies late-preclinical or Phase 1-ready assets from geographically dispersed biotechs, re-validates them through US regulatory pathways, and advances them toward value-inflection readouts. This positions Corbus as a specialized emerging-pharma development engine rather than a diversified asset manager or family-backed investment vehicle.